Drug discovery firm expands BioCity footprint
Nottingham-based early-stage drug discovery contract research organisation (CRO) Reach Separations has expanded its footprint at the BioCity campus in the city after reporting an increase demand for services.
Reach Separations specialises in chromatography for the analysis and purification of small molecules, and has added 1,580 sq ft of laboratory and office space on the ground floor of the Laurus Building at BioCity Nottingham, where the company has been based since 2012.
The company says it is on-track to record an all-time high in demand for its specialist chiral purification services as well as its annual turnover.
Reach Separations’ managing director Duncan Cliff said: “We have seen a significant increase in demand for large-scale chiral purification from clients across the UK and Europe, and the new dedicated large-scale laboratory space is designed specifically for chiral purification at 500g and over. We anticipate a continuation of this upward trend in demand for our chiral purification services, and alongside estimate our turnover will grow by at least 20% in 2021.
Reach Separations was founded eight years ago, when its team of four people took on one small laboratory in the Innovation Building at BioCity Nottingham.
The firm now occupies two large laboratories and office space, employ 13 people, recently added two new laboratory staff to the team and has more recruitment plans in the pipeline.
Victoria Coulthard, the company’s global head of business development, said: “Reach has a large and varied client base across the UK and Europe with whom we have adapted to new ways of working during the COVID-19 pandemic. We have successfully maintained high levels of communication with clients both established and new via new video conferencing software, which we believe is a crucial way to do business with Europe in the coming months, whilst also keeping our carbon footprint small.”
“BioCity Nottingham is in the ideal location at the heart of the UK and is home to several CROs, which has allowed us to collaborate and bring together our specialist drug discovery expertise to help clients expedite their drug discovery projects in spite of the COVID-19 lockdown.”
